Treating myeloma: the future is already here!

被引：8

作者：

Landgren, Ola ^{[1
]}

Korde, Neha ^{[1
]}

机构：

[1] Natl Canc Inst, Milan, Italy

来源：

BLOOD | 2012年 / 120卷 / 09期

关键词：

MULTIPLE-MYELOMA; THERAPY;

D O I：

10.1182/blood-2012-06-434571

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this issue of Blood, Jakubowiak and colleagues report outstanding results from a phase 1/2 study using carfilzomib-a next-generation proteasome inhibitor that selectively and irreversibly binds to the proteasome, targeting chymotrypsin-like activity-in combination with lenalidomide and low-dose dexamethasone in newly diagnosed multiple myeloma patients. The study shows excellent response rates, deep and durable responses, continued responses during treatment, and limited severe toxicities.(1)

引用

页码：1754 / 1756

页数：5

共 5 条

[1] A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma [J].

Jakubowiak, Andrzej J. ;

Dytfeld, Dominik ;

Griffith, Kent A. ;

Lebovic, Daniel ;

Vesole, David H. ;

Jagannath, Sundar ;

Al-Zoubi, Ammar ;

Anderson, Tara ;

Nordgren, Brian ;

Detweiler-Short, Kristen ;

Stockerl-Goldstein, Keith ;

Ahmed, Asra ;

Jobkar, Terri ;

Durecki, Diane E. ;

McDonnell, Kathryn ;

Mietzel, Melissa ;

Couriel, Daniel ;

Kaminski, Mark ;

Vij, Ravi .

BLOOD, 2012, 120 (09) :1801-1809

[2] Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies [J].

Korde, Neha ;

Kristinsson, Sigurdur Y. ;

Landgren, Ola .

BLOOD, 2011, 117 (21) :5573-5581

[3] Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance [J].

Nair, Bijay ;

van Rhee, Frits ;

Shaughnessy, John D., Jr. ;

Anaissie, Elias ;

Szymonifka, Jackie ;

Hoering, Antje ;

Alsayed, Yazan ;

Waheed, Sarah ;

Crowley, John ;

Barlogie, Bart .

BLOOD, 2010, 115 (21) :4168-4173

[4] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma [J].

Richardson, Paul G. ;

Weller, Edie ;

Lonial, Sagar ;

Jakubowiak, Andrzej J. ;

Jagannath, Sundar ;

Raje, Noopur S. ;

Avigan, David E. ;

Xie, Wanling ;

Ghobrial, Irene M. ;

Schlossman, Robert L. ;

Mazumder, Amitabha ;

Munshi, Nikhil C. ;

Vesole, David H. ;

Joyce, Robin ;

Kaufman, Jonathan L. ;

Doss, Deborah ;

Warren, Diane L. ;

Lunde, Laura E. ;

Kaster, Sarah ;

DeLaney, Carol ;

Hideshima, Teru ;

Mitsiades, Constantine S. ;

Knight, Robert ;

Esseltine, Dixie-Lee ;

Anderson, Kenneth C. .

BLOOD, 2010, 116 (05) :679-686

[5]

Usmani SZ, LEUKEMIA, DOI [10.1038/leu.2012., DOI 10.1038/LEU.2012]

← 1 →